Pathophysiology and management of endometrial hyperplasia and carcinoma.
Endometrial cancer is currently the commonest pelvic malignancy affecting American women, most of whom share the same pathophysiologic basis, that is, unopposed estrogenic stimulation. The initial result of hyperestrogenism is the development of endometrial hyperplasia, which is reversible in most cases by appropriate hormonal therapy. Persistent stimulation eventually leads to atypical hyperplasia with nuclear atypia and invasive carcinoma. Because there is no cost-effective screening method for the detection of endometrial hyperplasia and carcinoma, it is essential to survey the high-risk population with appropriate diagnostic techniques. After diagnosis, therapy should be individualized based on pathologic findings (cell type and histologic grade) and extent of disease (International Federation of Gynaecologists and Obstetricians stage, depth of myometrial invasion, and pelvic and para-aortic lymph node status). Recent studies suggest that sex hormone receptors and nuclear DNA ploidy patterns provide useful prognostic information independent of histologic grade.
Department of Pathology, UCLA School of Medicine 90024-1732.
Y S
YS
Fu
J C
JC
Gambone
J S
JS
Berek
D000230:Adenocarcinoma / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D002277:Carcinoma / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D004714:Endometrial Hyperplasia / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D045166:Estradiol Congeners / Q000009:adverse effects; D005260:Female; D006801:Humans; D012307:Risk Factors; D014481:United States; D014594:Uterine Neoplasms / Q000209:etiology / Q000503:physiopathology / Q000628:therapy
D045166:Estradiol Congeners